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 A balancing act: Subsidising
treatment for Malaria
Public subsidies may be an effective way to increase
access to antimalarial drugs in sub-Saharan Africa, but
large subsidies are accompanied by the risk of
overtreatment – the use of subsidised drugs by malaria
negative patients. Research from Kenya provides useful
insights for policymakers considering these subsidies
Malaria kills nearly one million people every year, with the
greatest burden falling on young children in sub-Saharan Africa.
In this region resistance has developed to all but one class of
antimalarials, called artemisinin combination therapies (ACTs).
In order to support access to this life-saving medication, many
malaria-endemic countries now provide free ACTs through
public health facilities. But shortages are common, and the rural
poor often have to travel far and wait in long lines to access
treatment. As a result, many people treat presumed cases of
malaria with less effective antimalarials purchased from local
drug shops, which are more convenient and open longer hours.
Many of these shops do not stock ACTs, and if ACTs are
available, they are unsubsidised and therefore unaffordable for
the poor.
In this context, one way to increase access to ACTs would be to
subsidise them in both the public health and the retail sectors.
The risk of such a policy is that it could lead to a sharp increase
in overtreatment (use of ACTs by malaria negative patients),
especially since rural drug shops are often staffed by individuals
with minimal medical qualifications and access to malaria
diagnostic services is limited. The overtreatment risk could be
mitigated by jointly subsidising malaria treatment and malaria
diagnosis, but the effectiveness of such a policy would depend
on both demand for diagnosis and compliance with test results.
These observations raise a number of important questions:
would subsidised ACTs sold through the retail sector mostly go
to the malaria positive, or the malaria negative? Can the
subsidy level be used to target ACTs to the malaria positive?
Would an RDT subsidy improve targeting? Answering these
questions is essential for countries deciding whether to spend
scarce malaria control resources on retail-sector subsidies.
In 2009 Jessica Cohen, Pascaline Dupas and I conducted a
randomised evaluation in rural Kenya to shed light on these
issues. In our paper we randomly assigned households to one of
four different retail-sector ACT subsidy regimes: (i) no subsidy,
(ii) an 80 percent subsidy, (iii) an 88 percent subsidy, and (iv) a
92 percent subsidy (this corresponds to the original subsidy
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92 percent subsidy (this corresponds to the original subsidy
level targeted by the Kenyan government during a large scale
pilot of retail sector ACT subsidies). We also randomly assigned
a subset of households in groups ii-iv to receive either free or
heavily subsidised rapid diagnostic tests (RDTs) for malaria.
These tests can be easily performed by staff with minimal
medical training and are generally more accurate than
microscopy (the traditional method of malaria diagnosis) in
rural settings.
Our findings offer the following insights for policy:
1. A retail-sector ACT subsidy dramatically increases
overall use of ACTs.
Without a subsidy, only 19 percent of malaria-like illnesses are
treated with an ACT. This share increases to 35-42 percent
under a 80-92 percent subsidy, reflecting both positive changes
(use by patients with malaria) and negative changes (overuse by
malaria-negative patients).
2. The ACT subsidy level is a useful tool for targeting
medication to the truly malaria positive.
When the ACT subsidy is high (92 percent), use of the drug
increases among both children (who are very likely to have
malaria conditional on seeking treatment) and adults (who are
much less likely to have malaria conditional on seeking
treatment). Lower subsidy levels discourage adult purchases
while leaving ACT use among young children essentially
unchanged. As a result, reducing the ACT subsidy from 92 to
80 percent increases the share of retail-sector ACT takers who
test malaria positive from 56 to 75 percent without
meaningfully reducing the share of true malaria cases treated
with an ACT.
3. RDT subsidies may improve the efﬁcacy of ACT
subsidies, provided patients act on their results.
We find that households are very willing to take subsidised
RDTs – as a result the RDT subsidy doubles the share of illness
episodes tested for malaria – but most patients who received a
negative RDT result still chose to take ACTs anyway. As a
result, we find little evidence that the RDT subsidy reduces
overuse of ACTs by malaria-negative patients. Our study only
looks at very short-run compliance with RDT test results, and
most of the individuals in our sample had never heard of RDTs
before, so it is possible that RDT compliance would increase
over time as individuals learn about the accuracy of the test.
In sum, our results offer the following insights for policy-
makers grappling with whether (and by how much) to subsidise
ACTs and RDTs:
Retail-sector ACT subsidies can dramatically increase ACT
access among populations underserved by the public health
system.
Not all subsidy levels are created equal: if the subsidy is “too
low” malaria positive individuals will go untreated, while “too
high” a subsidy will result in overuse of ACTs by malaria-
negatives. Thus, finding the right subsidy level to balance these
concerns is key.
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concerns is key.
RDT subsidies may be a useful tool to improve the efficacy of an
ACT subsidy policy, but it is important to ensure that individuals
actually comply with their test results. Supporting interventions
meant to increase rates of RDT compliance could improve the
efficacy of an RDT subsidy policy, at least in the short run.
Overall, this is good news for countries with limited malaria
control budgets: retail-sector ACT subsidies can expand access
to those who need the drug most, but subsidies do not have to
be as large as initially planned by the policy community. Of
course, it is important to keep in mind that our study was
conducted in a rural, malaria-endemic area. Overuse of
subsidised ACTs and compliance with RDTs (and accordingly
the attractiveness of a retail-sector ACT subsidy) could be
different in wealthier, better-connected areas with a lower
malaria burden.
